Insight with Haslinda Amin 6/17/2025
Bloomberg Insight
Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
25 minutes ago
- Bloomberg
China's MiniMax Says Its New AI Reasoning Model Beats DeepSeek
Chinese AI upstart MiniMax released a new large language model, joining a slew of domestic peers inspired to surpass DeepSeek in the field of reasoning AI. The Shanghai-based company touted the efficiency of its new MiniMax-M1 model in handling complicated productivity tasks, claiming it outdoes all closed-source competitors from China in a statement. In several benchmarks presented by MiniMax, M1 also scored higher than DeepSeek's latest R1-0528 model.
Bloomberg
25 minutes ago
- Bloomberg
Softbank-Backed Lenskart Said to Near Filing for $1 Billion IPO
By and Baiju Kalesh Save Softbank Group Corp. -backed Lenskart Solutions Pvt, India's largest eyewear maker, is preparing to file preliminary documents in the coming weeks for an initial public offering that may fetch about $1 billion, according to people familiar with the matter. Lenskart is preparing to submit a draft red herring prospectus for the listing, which would value the company at about $10 billion, the people said, asking not to be identified because the information is private. Earlier this month, the company converted itself into a public limited entity as part of its IPO preparations.
Yahoo
29 minutes ago
- Yahoo
Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average
From a technical perspective, Verve Therapeutics (VERV) is looking like an interesting pick, as it just reached a key level of support. VERV recently overtook the 200-day moving average, and this suggests a long-term bullish trend. The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support or resistance level. Over the past four weeks, VERV has gained 27.9%. The company is currently ranked a Zacks Rank #2 (Buy), another strong indication the stock could move even higher. Looking at VERV's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 5 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on VERV for more gains in the near future. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Verve Therapeutics, Inc. (VERV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
